Lv21
154 积分 2025-01-14 加入
US FDA 505(b)(2) NDA clinical, CMC and regulatory strategy concepts to expedite drug development
1天前
已完结
The Development of Hsp90β-selective Inhibitors to Overcome Detriments Associated with pan-Hsp90 Inhibition
22天前
已完结
HSP90 at the hub of protein homeostasis: emerging mechanistic insights
22天前
已完结
The HSP90 chaperone machinery
23天前
已完结
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
28天前
已完结
Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design
1个月前
已完结
HSP90 Mediates Targeted Degradation of Nonclient Protein PARP1 for Breast Cancer Treatment
1个月前
已完结
Targeted Protein Degradation Induced by HEMTACs Based on HSP90
1个月前
已完结
Spotlight on 17‐AAG as an Hsp90 inhibitor for molecular targeted cancer treatment
1个月前
已完结
Modulating the Binding Kinetics of Bruton’s Tyrosine Kinase Inhibitors through Transition-State Effects
1个月前
已完结
皖公网安备34019202002308
